Clinical trial · Observational
ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma
ISTODAX® for Intravenous Infusion 10mg Drug Use Results Survey - Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT03742921CI-TRIAL-00072029completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To ascertain the safety and efficacy of Istodax® in actual clinical settings in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) who receive Istodax. 1. Planned registration period 4 years 2. Planned surveillance period 5 years and 6 months
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, T-Cell, Peripheral | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Istodax | Drug | Romidepsin | ALIAS |
Design
Arms and outcomes
Arms (1)
- label
- Relapsed or Refractory T-Cell Lymphoma patients with Istodax
- description
- Among patients with relapsed or refractory peripheral T-Cell lymphoma, patients who received Istodax will be targeted in this surveillance
- interventionNames
- Drug: Istodax
Primary outcomes (1)
- measure
- Adverse Events (AEs)
- timeFrame
- Up to approximately 5 years
- description
- Number of participants with adverse event
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: \- Patients who have been diagnosed with relapsed or refractory PTCL who receive Istodax for the first time. Exclusion Criteria: N/A
References
Publications (0)
Data not yet available
No reference posted for this study.